Search
Macitentan
go.drugbank.com/drugs/DB08932ApprovedInvestigational[L35890] It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] in part due to its lower risk of hepatotoxicity. … [L39105] It was subsequently approved by the FDA in March 2024.[L50622]
Alefacept
go.drugbank.com/drugs/DB00092ApprovedWithdrawnImmunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells,...
Belzutifan
go.drugbank.com/drugs/DB15463ApprovedInvestigationalBelzutifan received FDA approval for the treatment of select VHL-associated cancers on August 13, 2021. … Belzutifan is an inhibitor of hypoxia-inducible factor 2α (HIF-2α) used in the treatment of von Hippel-Lindau (VHL) disease-associated cancers.
Efanesoctocog alfa
go.drugbank.com/drugs/DB16662ApprovedInvestigational[L45379] The use of FVIII replacement products is beneficial in patients with hemophilia A; however, their quality of life can be affected due to frequent doses. … [A257464] Efanesoctocog alfa was designed to have an extended half-life, and to surpass the half-life ceiling to which other forms of recombinant FVIII are subjected due to their association with von Willebrand
Trovafloxacin
go.drugbank.com/drugs/DB00685ApprovedWithdrawnDue to its hepatotoxic potential, trovafloxacin was withdrawn from the market.
Phenmetrazine
go.drugbank.com/drugs/DB00830ApprovedIllicitA sympathomimetic drug used primarily as an appetite depressant. Its actions and mechanisms are similar to dextroamphetamine.
Dotatate gallium Ga-68
go.drugbank.com/drugs/DB13925ApprovedInvestigationalWithdrawn[A31358] Dotatate gallium 68 was developed by Advanced Accelerator Applications USA, Inc. and FDA approved in June 1, 2016. … Ga-68 dotatate has a high affinity for somatostatin-2 receptor and it is rapidly excreted from the nontarget sites which gives it an ideal candidate for imaging neuroendocrine tumors.
Zanubrutinib
go.drugbank.com/drugs/DB15035ApprovedInvestigational[A187958] Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017. … Zanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL,[
Mannitol
go.drugbank.com/drugs/DB00742ApprovedInvestigationalOn October 30, 2020, mannitol was approved by the FDA as add-on maintenance therapy for the control of pulmonary symptoms associated with cystic fibrosis in adult patients and is currently marketed for … Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables.
Synonyms: D-Mannitol, D-(-)-MannitolTaletrectinib
go.drugbank.com/drugs/DB18711ApprovedInvestigationalTaletrectinib is an orally available small molecule kinase inhibitor. … [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523]